Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spesolimab long-term extension in hidradenitis suppurativa
NCT04876391Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2021
- Primary completion
- Apr 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 2 trial of spesolimab in hidradenitis suppurativa (HS), sponsored by Boehringer Ingelheim. Started Aug 2021; status: completed.
02
Drugs
spesolimab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT04876391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04876391.